This prospective longitudinal study will follow participants with Multifocal Motor Neuropathy over time and collect data on their clinical outcomes, quality of life, and use of health care resources. Participants will follow their regular visit schedule with their treating physician, except for an optional second visit occurring 7 to 14 days after the start of the study to collect biomarker data. No IMP will be administered.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
To characterize MMN patient profiles for participants
Timeframe: up to 61 months
To assess the MMN disease management and disease course
Timeframe: up to 61 months
To assess outcome measures specific to MMN disease and their evolution over time
Timeframe: up to 61 months
To estimate the burden of MMN on participants' quality of life
Timeframe: up to 61 months
To estimate the economic burden for participants with MMN
Timeframe: up to 61 months
To collect data on relevant disease biomarkers
Timeframe: up to 61 months